In fact, ABL inhibitors such as imatinib showed extended benefit in patients presenting with the BCR–ABL fusion [20]; which led to the approval of imatinib (a.k.a., Gleevec) for the treatment of BCR–ABL-positive CML. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.